Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
Mar. 31, 2019	Mar. 31, 2018
Net cash flows from operating activities:
Net loss	$ (297)	$ (3,855)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization	4,351	4,376
Non-cash compensation	1,850	1,248
Deferred income taxes	(424)	(1,283)
Other non-cash adjustments to loss	737	810
Changes in operating assets and liabilities:
Receivables	(3,292)	(3,346)
Inventories and deferred preservation costs	1,396	2,954
Prepaid expenses and other assets	627	(215)
Accounts payable, accrued expenses, and other liabilities	(3,787)	(10,416)
Net cash flows provided by (used in) operating activities	1,161	(9,727)
Net cash flows from investing activities:
Capital expenditures	(1,194)	(2,116)
Other	(233)	(3)
Net cash flows used in investing activities	(1,427)	(2,119)
Net cash flows from financing activities:
Repayment of term loan	(696)	(707)
Proceeds from exercise of stock options and issuance of common stock	2,029	606
Redemption and repurchase of stock to cover tax withholdings	(2,376)	(1,512)
Other	(172)	(341)
Net cash flows used in financing activities	(1,215)	(1,954)
Effect of exchange rate changes on cash	320	439
Decrease in cash, cash equivalents, and restricted securities	(1,161)	(13,361)
Cash, cash equivalents, and restricted securities beginning of year	42,236	40,753
Cash, cash equivalents, and restricted securities end of year	$ 41,075	$ 27,392

The increase (decrease) during the reporting period in deferred preservation costs and inventories, associated with underlying transactions that are classified as operating activities. Preservation costs consists primarily of directlabor and materials and indirect costs which are deferred until revenue is recognized upon shipment of the tissue to an implanting facility.

No definition available.